Nexavar sorafenib: Phase III data

The double-blind, international Phase III RESILIENCE trial in 537 patients with locally advanced or metastatic HER2-negative breast cancer showed that 600 mg oral Nexavar daily plus capecitabine missed the primary endpoint of improving PFS vs. placebo plus capecitabine. The trial enrolled patients who are resistant to or have failed prior taxane therapy, and resistant to or have failed anthracycline or for whom further anthracycline is not indicated. The partners could not be reached for next steps. ...